Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefan Welter

Showing results (51-60 of 69) with videos related to

Pageof 7
Sort By:
Histopathology|June 12, 2023
Proteomic analysis identifies argininosuccinate synthetase 1 and special AT-rich sequence binding protein 1 as reliable markers for the immunohistochemical distinction between WHO types A and B3 thymomasFelix Bremmer, Hanibal Bohnenberger, Peter Findeisen, et al.
Journal of Thoracic Disease|April 30, 2015
Accelerated radiotherapy and concurrent chemotherapy for patients with contralateral central or mediastinal lung cancer relapse after pneumonectomyChristoph Pöttgen, Jehad Abu Jawad, Eleni Gkika, et al.
BMC Medicine|November 16, 2021
Functional apoptosis profiling identifies MCL-1 and BCL-xL as prognostic markers and therapeutic targets in advanced thymomas and thymic carcinomasDenise Müller, Paolo Mazzeo, Raphael Koch, et al.
Respiration; International Review of Thoracic Diseases|January 7, 2021
Joint Statement of the German Respiratory Society and German Society of Thoracic Surgery in Cooperation with the German Radiological Society: Structural Prerequisites of Centres for Interventional Treatment of EmphysemaWolfgang Johannes Gesierich, Kaid Darwiche, Felix Döllinger, et al.
BMC Cancer|May 7, 2015
Prognostic model for long-term survival of locally advanced non-small-cell lung cancer patients after neoadjuvant radiochemotherapy and resection integrating clinical and histopathologic factorsChristoph Pöttgen, Martin Stuschke, Britta Graupner, et al.
Cancers|October 14, 2022
Phosphoproteomic Analysis Identifies TYRO3 as a Mediator of Sunitinib Resistance in Metastatic ThymomasStefan Küffer, Jessica Grabowski, Satoru Okada, et al.
Cancers|December 30, 2025
Refining Risk Stratification and Surveillance Strategies in Pleuropulmonary Solitary Fibrous Tumors-An International, Retrospective, Multicenter AnalysisRahel S Decker, Daniel Baum, Stephan Richter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2016
Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Non-Small-Cell Lung CancerChristoph Pöttgen, Thomas Gauler, Alexander Bellendorf, et al.
Lung Cancer (Amsterdam, Netherlands)|August 21, 2013
10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicenter phase-II trial (CISTAXOL)Wilfried Ernst Erich Eberhardt, Thomas Christoph Gauler, Cecile Lepechoux, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|November 20, 2014
Clinical management of atypical carcinoid and large-cell neuroendocrine carcinoma: a multicentre study on behalf of the European Association of Thoracic Surgeons (ESTS) Neuroendocrine Tumours of the Lung Working Group†Pier Luigi Filosso, Ottavio Rena, Francesco Guerrera, et al.
Pageof 7

Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
Histopathology|June 12, 2023
Proteomic analysis identifies argininosuccinate synthetase 1 and special AT-rich sequence binding protein 1 as reliable markers for the immunohistochemical distinction between WHO types A and B3 thymomasFelix Bremmer, Hanibal Bohnenberger, Peter Findeisen, et al.
Journal of Thoracic Disease|April 30, 2015
Accelerated radiotherapy and concurrent chemotherapy for patients with contralateral central or mediastinal lung cancer relapse after pneumonectomyChristoph Pöttgen, Jehad Abu Jawad, Eleni Gkika, et al.
BMC Medicine|November 16, 2021
Functional apoptosis profiling identifies MCL-1 and BCL-xL as prognostic markers and therapeutic targets in advanced thymomas and thymic carcinomasDenise Müller, Paolo Mazzeo, Raphael Koch, et al.
Respiration; International Review of Thoracic Diseases|January 7, 2021
Joint Statement of the German Respiratory Society and German Society of Thoracic Surgery in Cooperation with the German Radiological Society: Structural Prerequisites of Centres for Interventional Treatment of EmphysemaWolfgang Johannes Gesierich, Kaid Darwiche, Felix Döllinger, et al.
BMC Cancer|May 7, 2015
Prognostic model for long-term survival of locally advanced non-small-cell lung cancer patients after neoadjuvant radiochemotherapy and resection integrating clinical and histopathologic factorsChristoph Pöttgen, Martin Stuschke, Britta Graupner, et al.
Cancers|October 14, 2022
Phosphoproteomic Analysis Identifies TYRO3 as a Mediator of Sunitinib Resistance in Metastatic ThymomasStefan Küffer, Jessica Grabowski, Satoru Okada, et al.
Cancers|December 30, 2025
Refining Risk Stratification and Surveillance Strategies in Pleuropulmonary Solitary Fibrous Tumors-An International, Retrospective, Multicenter AnalysisRahel S Decker, Daniel Baum, Stephan Richter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2016
Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Non-Small-Cell Lung CancerChristoph Pöttgen, Thomas Gauler, Alexander Bellendorf, et al.
Lung Cancer (Amsterdam, Netherlands)|August 21, 2013
10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicenter phase-II trial (CISTAXOL)Wilfried Ernst Erich Eberhardt, Thomas Christoph Gauler, Cecile Lepechoux, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|November 20, 2014
Clinical management of atypical carcinoid and large-cell neuroendocrine carcinoma: a multicentre study on behalf of the European Association of Thoracic Surgeons (ESTS) Neuroendocrine Tumours of the Lung Working Group†Pier Luigi Filosso, Ottavio Rena, Francesco Guerrera, et al.
Pageof 7